A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease

Chagas disease (ChD), caused by the hemoflagellate parasite Trypanosoma cruzi, affects six to seven million people in Latin America. Lately, it has become an emerging public health concern in nonendemic regions such as North America and Europe. There is no prophylactic or therapeutic vaccine as yet,...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:NPJ Vaccines
Asıl Yazarlar: Portillo, Susana, Zepeda, Brenda G., Iniguez, Eva, Olivas, Janet J., Karimi, Nasim H., Moreira, Otacilio C., Marques, Alexandre F., Michael, Katja, Maldonado, Rosa A., Almeida, Igor C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6430786/
https://ncbi.nlm.nih.gov/pubmed/30911415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41541-019-0107-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller